PERCIST in Perspective
暂无分享,去创建一个
Richard L Wahl | R. Wahl | J. O | Joo Hyun O
[1] D. Choi,et al. Prognostic Value of Volume-Based Metabolic Parameters Measured by 18F-FDG PET/CT of Pancreatic Neuroendocrine Tumors , 2014, Nuclear Medicine and Molecular Imaging.
[2] R. Wahl,et al. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.
[3] J. Min,et al. Intratumoral Metabolic Heterogeneity for Prediction of Disease Progression After Concurrent Chemoradiotherapy in Patients with Inoperable Stage III Non-Small-Cell Lung Cancer , 2014, Nuclear Medicine and Molecular Imaging.
[4] X. Ling,et al. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[5] Jeanne Kowalski,et al. Assessment of Interobserver Reproducibility in Quantitative 18F-FDG PET and CT Measurements of Tumor Response to Therapy , 2009, Journal of Nuclear Medicine.
[6] H. Nakanishi,et al. Impact of total lesion glycolysis measured by 18F-FDG-PET/CT on overall survival and distant metastasis in hypopharyngeal cancer. , 2016, Oncology letters.
[7] Thomas Beez,et al. Diagnostic Performance of 18F-FET PET in Newly Diagnosed Cerebral Lesions Suggestive of Glioma , 2013, The Journal of Nuclear Medicine.
[8] Bruce D Cheson,et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] T. Watabe,et al. Evaluation of Response to Neoadjuvant Chemotherapy for Esophageal Cancer: PET Response Criteria in Solid Tumors Versus Response Evaluation Criteria in Solid Tumors , 2012, The Journal of Nuclear Medicine.
[10] M. Gönen,et al. Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[11] Qiyong Ding,et al. PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST). , 2014, Journal of thoracic disease.
[12] H. McArthur,et al. The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by 18F-FDG PET/CT Using PERCIST , 2016, The Journal of Nuclear Medicine.
[13] Ji-Hoon Jung,et al. Prognostic Significance of Intratumoral Metabolic Heterogeneity on 18F-FDG PET/CT in Pathological N0 Non–Small Cell Lung Cancer , 2015, Clinical nuclear medicine.
[14] R. Wahl,et al. Optimum Lean Body Formulation for Correction of Standardized Uptake Value in PET Imaging , 2014, The Journal of Nuclear Medicine.
[15] H. Chung,et al. Prognostic value of total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with uterine carcinosarcoma , 2016, European Radiology.
[16] Martin A Lodge,et al. Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. , 2016, Radiology.
[17] Binsheng Zhao,et al. Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] K. Herholz,et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.
[19] Nai-Ming Cheng,et al. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib , 2016, European Journal of Nuclear Medicine and Molecular Imaging.